News Astellas' Iveric takeover rewarded with FDA nod for GA drug The FDA has approved a new drug for sight-robbing disease geographic atrophy from Astellas, just a few weeks after the company
News Astellas cuts $5.9bn deal to buy Iveric Bio Astellas Pharma has agreed its largest-ever acquisition, buying US biotech Iveric Bio in a deal that continues to build its presence in the ophthalmology sector,
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.